第三次复发的世界卫生组织1级脊髓膜瘤:手术或根治性放疗后的病例系列与临床结局
回顾性分析2008至2021年48例第三次进展的WHO 1级脊髓膜瘤患者,31例接受第三次手术、17例接受根治性放疗(中位剂量54 Gy/30次)。中位随访30个月,36个月无进展生存率手术组77.4%与放疗组76.4%相当;放疗组疼痛控制更优,未观察到放射性脊髓病。
要点
- 第三次复发WHO 1级脊髓膜瘤中,手术与根治性放疗36个月无进展生存率相当(77.4% vs 76.4%)。
- 放疗组疼痛控制更优,未观察到放射性脊髓病。
- 手术组肿瘤更大(中位1.8 cm vs 1 cm,P < 0.001),神经功能改善比例手术组79.1%、放疗组58.3%。
核心结论
- 对于选择性复发性脊髓膜瘤患者,根治性放疗似乎是第三次手术的可行替代方案,提供相当的无进展生存和可控的毒性。
- 需要更大规模的前瞻性研究来验证这些发现并完善复发性脊髓膜瘤的治疗方法。
研究设计与样本
- 回顾性综述,纳入2008年至2021年间48例第三次进展的WHO 1级脊髓膜瘤患者。
- 纳入标准要求既往接受过第二次手术且病理确认为WHO 1级;排除既往手术后接受放疗或病理升级为WHO 2级或3级的患者。
- 31例接受第三次手术,17例接受根治性放疗(中位剂量54 Gy/30次);中位随访30个月。
- 采用Kaplan-Meier生存分析评估无进展生存,并记录治疗相关毒性。
主要发现
- 36个月无进展生存率手术组77.4% vs 放疗组76.4%。
- 手术组肿瘤更大(中位1.8 cm vs 1 cm,P < 0.001)。
- 神经功能改善手术组79.1% vs 放疗组58.3%。
- 放疗组疼痛控制更优,未观察到放射性脊髓病。
临床怎么用
- 作者认为,对于选择性复发性脊髓膜瘤患者,根治性放疗似乎是第三次手术的可行替代方案。
- 作者建议需要更大规模的前瞻性研究来验证这些发现并完善治疗方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spinal meningiomas (SMs) are rare, predominantly benign tumors that account for 1.2%-12.7% of all meningiomas. While surgical resection is the primary treatment, recurrence occurs in a subset of patients, necessitating subsequent therapies such as reoperation or definitive radiation therapy (RT). This study evaluates the outcomes of definitive RT versus third surgery for recurrent World Health Organization (WHO) grade 1 SM, focusing on progression-free survival (PFS) and treatment-related toxicities. METHODS: A retrospective review of 48 patients with third progression of WHO grade 1 SM was conducted between 2008 and 2021. Inclusion criteria required prior second surgery and a confirmed pathology of WHO grade 1. Patients who received RT after earlier surgeries or whose pathology upgraded to WHO grade 2 or 3 were excluded. Data on demographics, tumor characteristics, surgical outcomes, and RT parameters were analyzed. PFS was assessed using Kaplan-Meier survival analysis, and treatment-related toxicities were recorded. RESULTS: Of the 48 patients, 31 underwent third surgery and 17 received definitive RT (median dose: 54 Gy in 30 fractions). Median follow-up was 30 months. PFS at 36 months was comparable between surgery (77.4%) and RT (76.4%). Tumor size was larger in the surgery group (median 1.8 cm vs. 1 cm, P < 0.001). Neurological improvements were noted in 79.1% of surgery patients and 58.3% of RT patients. RT offered superior pain control, with no cases of radiation myelopathy observed. CONCLUSIONS: Definitive RT appears to be a feasible alternative to third surgery for recurrent SM in selected patients, providing comparable PFS and manageable toxicities. Larger prospective studies are needed to validate these findings and refine treatment approaches for recurrent SM.
引用
- Haisraely O, Jaffe M, Taliansky A, et al. Third Recurrent World Health Organization 1 Spinal Meningiomas: Case Series and Clinical Outcomes Following Surgery or Definitive Radiotherapy. World Neurosurg. 2025. PMID: 39889955. doi:10.1016/j.wneu.2025.123704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。